|  | 
| Azedra (iobenguane I 131) in patients with malignant, recurrent and/or unresectable pheochromocytoma or paraganglioma (PPGL): Updated efficacy and safety results from a multi-center, open-label, pivotal phase 2 study. | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
| Research Funding - Progenics (Inst) | 
|  | 
|  | 
| Research Funding - Progenics (Inst) | 
|  | 
|  | 
| Research Funding - Progenics (Inst) | 
|  | 
|  | 
| Research Funding - Progenics (Inst) | 
|  | 
|  | 
|  | 
| Stock and Other Ownership Interests  - Progenics | 
|  | 
|  | 
|  | 
| Stock and Other Ownership Interests  - Progenics | 
|  | 
|  | 
|  | 
| Stock and Other Ownership Interests  - Progenics | 
|  | 
|  | 
|  | 
| Stock and Other Ownership Interests  - Progenics | 
|  | 
|  | 
| No Relationships to Disclose | 
|  | 
|  | 
|  | 
|  | 
| Stock and Other Ownership Interests  - Progenics | 
|  | 
|  | 
|  | 
|  | 
| Stock and Other Ownership Interests  - Progenics | 
|  | 
|  | 
| Research Funding - Progenics (Inst) |